Silence Therapeutics (SLN) Operating Margin (2020 - 2026)
Silence Therapeutics recorded quarterly Operating Margin of 3729.15% in Q1 2026, down 102.25% quarter-over-quarter from 166076.47% in Q4 2025, and up 1627719.0% year-over-year from N/an in Q1 2025.
Silence Therapeutics' Operating Margin history runs 7 years deep, the most recent figure standing at 3729.15% for Q1 2026.
- In Q1 2026, Operating Margin rose 1627719.0% year-over-year to 3729.15%; the TTM figure through Mar 2026 stood at 1162.94% (down 85290.0% YoY), while the FY2025 annual figure was 3962.43%, down 381606.0% from the prior year.
- Operating Margin came in at 3729.15% for Q1 2026 at Silence Therapeutics, down from 166076.47% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 166076.47% in Q4 2025 to a low of 20006.34% in Q1 2025.
- A 5-year average of 6248.53% and a median of 404.06% in 2022 frame the typical range for Operating Margin.
- Across the five-year window, Operating Margin soared 2000000000 bps in 2022 and sank 1997079 bps in 2025, its largest moves.
- Silence Therapeutics' Operating Margin stood at 230.03% in 2022, then plunged by 175 bps to 633.59% in 2023, then jumped by 97 bps to 17.2% in 2024, then soared by 965763 bps to 166076.47% in 2025, then plunged by 102 bps to 3729.15% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 3729.15%, 166076.47%, and 16505.66% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Silence Therapeutics | 924.61 Mn | 854.53 Mn | 411,000.00 | -3,729.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,729.15% |
| Dec 31, 2025 | 166,076.47% |
| Sep 30, 2025 | -16,505.66% |
| Jun 30, 2025 | -11,981.50% |
| Mar 31, 2025 | -20,006.34% |
| Dec 31, 2024 | -17.20% |
| Sep 30, 2024 | -2,002.47% |
| Jun 30, 2024 | -3,059.22% |
| Mar 31, 2024 | -35.55% |
| Dec 31, 2023 | -633.59% |
| Sep 30, 2023 | -453.86% |
| Jun 30, 2023 | -125.85% |
| Mar 31, 2023 | -106.81% |
| Dec 31, 2022 | -230.03% |
| Sep 30, 2022 | -404.06% |
| Jun 30, 2022 | -386.74% |
| Mar 31, 2022 | -173.40% |
| Dec 31, 2021 | -329.91% |
| Sep 30, 2021 | -389,226,869.46% |
| Jun 30, 2021 | -478.60% |
| Mar 31, 2021 | -297.11% |
| Dec 31, 2020 | -654.20% |
| Sep 30, 2020 | -481.29% |